Clinical trials: Metabolism Disorders
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer, Obesity
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
To determine the effect of weight on doxorubicin and cyclophosphamide plasma clearance in participants who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I obese (BMI 25-34.9 kg/m2), or class II-III…
- Trial name
- NCT01537029
- Testing
- Doxorubicin, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Texas Tech University Health Sciences Center
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
- Trial name
- NCT03602261
- Testing
- Calcifediol Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 44 people
- Sponsor
- OPKO Health, Inc.
Type 1 Diabetes Mellitus, Hypoglycemia
24/7 Closed-loop in Older Subjects With Type 1 Diabetes
The main objective of this open-label, multi-centre, randomised, crossover design study is to determine whether automated day and night closed-loop insulin delivery for 16 weeks under free living conditions is safer and more…
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia, Arrythmia
- Trial name
- DAN06 (NCT04025762)
- Testing
- Hybrid closed-loop system (CamAPS FX), Sensor augmented pump therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- University of Cambridge
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
The purpose of this study is to evaluate the long-term safety of trelagliptin tablets in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal failure in the routine clinical setting.
- Trial name
- NCT04285983
- Testing
- Trelagliptin
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- Takeda
Gout
Long-Term Safety of Febuxostat in Subjects With Gout.
The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout.
- Trial name
- FOCUS (NCT00174941)
- Testing
- Febuxostat
- Volunteers
- 116 people
- Sponsor
- Takeda
Childhood Obesity
Physical Activity and Screen-Time Regulations in Childcare Centers - Aim 1
The goal of this project is to examine the physical activity and screen-time environment of licensed childcare centers before and after the enactment of new state regulations.
- Trial name
- Pause and Play (NCT02751788)
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Pennington Biomedical Research Center
Diabetes, Weightloss
The WISE (Weightloss Intervention Surgical Effects) Brain Study
This study is being done to learn about the changes that weight loss causes on brain function, memory and thinking ability in adults. The study does NOT cover any costs associated with bariatric surgery.
- Trial name
- WISEBrain (NCT02137070)
- Testing
- Bariatric Surgery Candidates, Non surgical/Community volunteers
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- University of Florida
Stroke
Strength Training for Skeletal Muscle Adaptation After Stroke
Chronically disabled stroke survivors experience accelerated skeletal muscle atrophy and other detrimental changes to muscle and surrounding tissues on the paretic side.
- Trial name
- NCT00827827
- Testing
- Exercise- Strength Training, Exercise- Stretching Control
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- VA Office of Research and Development
Lipid Metabolism Disorders
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This study is to demonstrate therapeutic comparability of Fluvastatin sodium Extended Release Tablets 80 mg QD and Fluvastatin sodium Immediate Release Capsules 40 mg BID in LDL-C lowering from baseline to week 12 (endpoint) in…
- Trial name
- NCT01551173
- Testing
- Fluvastatin sodium
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, Diabetic Macular Edema
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Trial name
- ZETA-1 (NCT04692688)
- Testing
- APX3330
- Where
- 24 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Gout
RDEA3170 and Allopurinol Combination Study in Gout Subjects
This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of RDEA3170 or allopurinol alone and in…
- Trial name
- NCT02279641
- Testing
- RDEA3170 10 mg, allopurinol 300 mg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ardea Biosciences, Inc.
Hypoglycemia, Complications of Bariatric Procedures
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe…
- Trial name
- NCT02733588
- Testing
- G-Pump™ (glucagon infusion)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes, Obesity
Metabolomic Analysis of Hepatic Insulin Resistance
This is a pilot study to show that it is possible to identify the specific types of fats in blood, adipose tissue, and liver tissue.
- Trial name
- NCT01833403
- Testing
- Hyperinsulinemic-euglycemic clamp
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Cardiovascular Disease, Hyperlipidemia
Effect of Evolocumab on Coronary Atherosclerosis
This study will quantify changes in coronary plaque volumes and plaque composition in patients treated with evolocumab. Previous intravascular ultrasound studies have shown that treatment with a lipid-lowering PCSK9 enzyme…
- Trial name
- NCT03689946
- Testing
- Evolocumab, 18F-NaF PET, CCTA
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Cedars-Sinai Medical Center
Type 2 Diabetes
A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)
This study is a six-month, prospective, randomized, multicenter, single- blind, controlled clinical study to evaluate the effect of three low-doses of Naturlose (Tagatose) on glycemic control and safety in subjects with Type 2…
- Trial name
- NCT00961662
- Testing
- D-Tagatose
- Where
- 13 sites in United States, India
- Volunteers
- 161 people
- Sponsor
- Robert Lodder
Type 2 Diabetes, Coronary Artery Disease
Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects
This pilot trial seeks to obtain preliminary data on the effects of eicosapentaenoic acid (EPA) (4g/d) on endothelial function measured via endopat2000 after 12 weeks of intervention among adults with elevated triglycerides and…
- Trial name
- NCT02422446
- Testing
- Icosapent ethyl
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Obesity, Leptin Resistance
Effect of Increased Free Fatty Acids on Leptin Function
Obese people have elevated levels of the hormone leptin. Despite this, they seem to be resistant to the effects of this hormone, which usually regulates appetite and energy expenditure.
- Trial name
- NCT01520454
- Testing
- Saline, Intralipid, Water
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773 compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM with insufficient glycaemic control.
- Trial name
- NCT01177813
- Testing
- BI 10773, BI 10773 open label
- Where
- 124 sites in United States, Belgium and 7 more
- Volunteers
- 986 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.